Lisata Therapeutics (LSTA) Non-Current Deferred Tax Liability (2016 - 2017)
Lisata Therapeutics (LSTA) has disclosed Non-Current Deferred Tax Liability for 8 consecutive years, with $1.1 million as the latest value for Q1 2017.
- For the quarter ending Q1 2017, Non-Current Deferred Tax Liability rose 13.61% year-over-year to $1.1 million, compared with a TTM value of $1.1 million through Mar 2017, up 13.61%, and an annual FY2016 reading of $1.1 million, up 14.8% over the prior year.
- Non-Current Deferred Tax Liability was $1.1 million for Q1 2017 at Lisata Therapeutics, up from $1.1 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $35.5 million in Q4 2013 and bottomed at $932662.0 in Q4 2015.
- Average Non-Current Deferred Tax Liability over 5 years is $9.5 million, with a median of $4.1 million recorded in 2013.
- The sharpest move saw Non-Current Deferred Tax Liability soared 369.11% in 2014, then crashed 94.87% in 2015.
- Year by year, Non-Current Deferred Tax Liability stood at $35.5 million in 2013, then tumbled by 48.87% to $18.2 million in 2014, then plummeted by 94.87% to $932662.0 in 2015, then rose by 14.8% to $1.1 million in 2016, then rose by 4.63% to $1.1 million in 2017.
- Business Quant data shows Non-Current Deferred Tax Liability for LSTA at $1.1 million in Q1 2017, $1.1 million in Q4 2016, and $1.1 million in Q3 2016.